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Cyclosporine A attenuates the natriuretic action of loop
diuretics by inhibition of renal COX-2 expression
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Cyclosporine A attenuates the natriuretic action of loop diuret-
ics by inhibition of renal COX-2 expression.
Background. It is known that inhibition of cyclooxygenase
(COX) impairs the renal actions of loop diuretics. Recently, we
found that cyclosporine A (CsA) inhibits renal COX-2 expres-
sion. Therefore, we examined the interferences of CsA with the
renal actions of loop diuretics.
Method. We investigated the renal effects of furosemide
administration (12 mg/day subcutaneously) in male Sprague-
Dawley rats receiving in addition vehicle, CsA (15 mg/kg ×
day), rofecoxib (10 mg/kg × day), or a combination of both.
Results. CsA, rofecoxib, and their combination lowered the
furosemide-induced increase of prostaglandin E2 (PGE2) and
of 6-keto prostaglandin F1a (6-keto PGF1a) excretion by 55%
and by 70%. They also lowered furosemide stimulated renal
excretion of sodium and water by about 65% and 60%. Basal as
well as furosemide-induced stimulation of plasma renin activity
(PRA) and of renal renin mRNA was further enhanced by CsA.
In contrast, rofecoxib attenuated the furosemide-induced rise
of PRA and of renin mRNA, both in the absence and in the
presence of CsA. In addition, the increase in plasma 6-keto
PGF1a levels by furosemide was further enhanced by CsA and
was attenuated by rofecoxib.
Conclusion. Taken together, our data suggest that CsA acts as
an antinatriuretic, likely by the inhibition of COX-2–mediated
renal prostanoid formation. Since the furosemide-induced stim-
ulation of the renin system is not attenuated by CsA but by
COX-2 inhibition, we speculate that extrarenal COX-2–derived
prostanoids may be involved in the stimulation of the renin sys-
tem by CsA and by loop diuretics.
Loop diuretics such as furosemide exert diverse renal
effects, which in part involve prostanoids [1]. It is known
that natriuresis caused by impaired salt transport in the
loop of Henle as well as the concomitant stimulation of
the renin system by furosemide are attenuated or even
abrogated by inhibition of cyclooxygenase (COX) in hu-
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mans and laboratory animals [2, 3]. More recent results
suggest that prostanoids, which apparently favor natri-
uresis and diuresis and which concomitantly stimulate
renin synthesis and secretion, are mainly produced by the
cyclooxygenase-2 (COX-2) isoform [4]. It has been shown
in this context that selective COX-2 inhibitors attenuate
natriuresis and the stimulation of the renin system in pa-
tients suffering from the Bartter syndrome as well as in
men and rats treated with the loop diuretic furosemide
[5–8]. COX-2 is expressed in the normal kidney and its ex-
pression in the loop of Henle, including the macula densa
region, is further enhanced in Bartter patients as well as
in rats treated with furosemide [4–9]. The close anatomic
relation between COX-2 expressing macula densa cells
and renin-producing juxtaglomerular cells has led to the
concept that COX-2–derived prostanoids from the mac-
ula densa may be importantly involved in the regulation
of renin secretion and renin synthesis [10]. Whether such
a linkage really exists is still a matter of debate, since find-
ings have previously been reported supporting [10, 11] or
not supporting [12–15] such a role.
We have previously observed that treatment with cal-
cineurin inhibitors, such as cyclosporine A (CsA) and
tacrolimus strongly attenuates the expression of COX-2
in the rat kidney and reduces renal tissue prostanoid for-
mation [16]. In view of the prostanoid dependency of the
renal effects of loop diuretics [5, 6], it appeared of inter-
est to us to find out if and how the renal effects of loop
diuretics are altered in the presence of the calcineurin
inhibitor CsA.
METHODS
In vivo experiments
Male Sprague-Dawley rats (Charles River, Sulzfeld,
Germany) weighing 150 to 175 g were used for this
study. Rats received standard rat chow (0.6% NaCl wt/wt)
(Trouw Nutrition, Burgheim, Germany) and had free ac-
cess to tap water and a solution containing 0.9% sodium
chloride and 0.1% potassium chloride. Body weight, wa-
ter intake, food intake, and systolic blood pressure (tail
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cuff method) were monitored daily. For urinary measure-
ments, rats were housed individually in metabolic cages
during the last 2 days of treatment. Rats were divided
into eight groups, consisting of eight rats each and treated
as follows: group 1 were controls; group 2 were given
CsA (15 mg/kg × day for 5 days) orally via a stomach
tube; group 3 were given rofecoxib (10 mg/kg × day for
5 days) orally via a stomach tube; group 4 were given CsA
and rofecoxib for 5 days; group 5 were given furosemide
(12 mg/day) chronically infused subcutaneously via os-
motic minipump (model 2ML1) (Alzet Osmotic Pumps,
Durect Corporation, Cupertino, CA, USA) for 5 days;
group 6 were given furosemide and CsA; group 7 were
given furosemide and rofecoxib; and group 8 were given
furosemide, CsA, and rofecoxib.
Samples
Rats were sacrificed by decapitation during anesthesia
with sevoflurane. Blood was collected into ethylenedi-
aminetetraacetic acid (EDTA) tubes. The kidneys were
quickly removed and were cut in longitudinal halves. Cor-
tex and outer and inner medulla were dissected with a
scalpel blade under a stereomicroscope, frozen in liquid
nitrogen, and stored at −80◦C until extraction of total
RNA.
Ribonuclease protection assays for b-actin, COX-2,
COX-1, and renin mRNA
Cytoplasmic b-actin, COX-1, COX-2, and renin
mRNA were determined by specific RNase protection
assays as described previously [17].
Determination of plasma renin activity (PRA)
PRA was determined using a commercially avail-
able radioimmunoassay (RIA) kit (Sorin Biomedica,
Du¨sseldorf, Germany).
Determination of prostanoids
Plasma 6-keto prostaglandin F1a (6-keto PFG1a) lev-
els and daily urinary prostanoid excretion [thromboxane
B2(TxB2), 6-keto PGF1a , and prostaglandin E2 (PGE2)]
were assayed by using monoclonal enzyme immunoassay
(EIA) kits (Cayman Chemical, Ann Arbor, MI, USA).
Tissue levels of prostanoids were assayed as described
previously [18].
Determination of urinary sodium and potassium
Urinary sodium and potassium concentrations were
determined by flame photometry using a low tempera-
ture, single-channel emission flame photometer (PFP7)
(Jenway, Dunmow, Essex, UK). Excretion rates for
sodium and potassium were calculated.
Determination of furosemide levels
Furosemide was determined by reversed-phase high-
performance liquid chromatography (HPLC) adapting
a published method for the determination of ketorolac
[19], which in turn was used as internal standard. In
brief, serum or urine was mixed with ZnSO4/methanol
as described [19]. Renal tissue was homogenized
(Ultra-Turrax, IKA, Freiburg, Germany) in 5 volumes
(weight/volume) of 5% aqueous ZnSO4/methanol (20:80;
vol/vol). Following centrifugation, 10 to 20 lL of the su-
pernatant was injected into the HPLC system. Chromato-
graphic separation was performed using a reversed-phase
Luna 5 C18 column (internal diameter 150 × 4.6 mm)
(Phenomenex, Aschaffenburg, Germany) with acetoni-
trile/water (40:60, vol/vol, pH 2.8, with 85% H3PO4) as
eluent and photometric detection at 235 nm. At a flow
rate of 1 mL/min (column temperature 30◦C) furosemide
eluted after 5 minutes, and ketorolac (internal standard)
after 6 minutes.
Immunoblotting for b-actin, COX-1, and COX-2 protein
One hundred micrograms of total renocortical protein
were loaded per lane, separated by an 8% sodium do-
decyl sulfate (SDS)-polyacrylamide gel and transferred
onto a nitrocellulose membrane (Bio-Rad, Hercules, CA,
USA). Membranes were blocked overnight at 4◦C and in-
cubated for 2 hours at room temperature with the primary
antibody (COX-2 murine polyclonal AB, 1:500) (Cay-
man Chemicals) (COX-1 murine polyclonal AB 1:500)
(Cayman Chemicals) and a horseradish peroxidase
(HPR)-labeled secondary antibody (goat antirabbit
IgG; 1:500) (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA). Detection was achieved by en-
hanced chemiluminescence (ECL) (Amersham, Braun-
schweig, Germany). The band intensities were quantified
densitometrically. For the detection of b-actin pro-
tein (mouse monoclonal AB, 1:2000) (Sigma Chemi-
cal Co., St. Louis, MO, USA) 20 lg of protein were
analyzed.
Creatinine clearance
Plasma and urinary concentrations of creatinine were
measured with the Jaffe reaction. Clearances were
calculated.
Statistical analysis
Data are presented as mean ± SEM. Levels of signifi-
cance were calculated by analysis of variance (ANOVA)
followed by Bonferroni’s test for multiple comparisons.
P < 0.05 was considered statistically significant.
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Table 1. Systolic blood pressure, heart rate, daily body weight gain, hematocrit, and creatinine clearance in the different groups
Systolic blood Heart rate Daily body weight Hematocrit Creatinine
pressure mm Hg bpm gain g/day % clearance mL/min
Control 122 ± 5 388 ± 12 8.2 ± 0.8 38.1 ± 2.0 0.60 ± 0.09
Cyclosporine A 141 ± 5a 432 ± 13a 6.5 ± 0.7a 39.5 ± 1.5 0.52 ± 0.09
Rofecoxib 139 ± 4a 395 ± 10 8.0 ± 0.6 37.8 ± 2.5 0.52 ± 0.07
Cyclosporine A + rofecoxib 145 ± 6a 435 ± 11a 6.3 ± 0.5a 39.0 ± 1.9 0.53 ± 0.08
Furosemide 117 ± 4 428 ± 13a 4.5 ± 0.4a 39.1 ± 1.5 0.52 ± 0.09
Furosemide + cyclosporine A 129 ± 5 462 ± 16b 1.8 ± 0.3b 42.0 ± 2.5 0.42 ± 0.09
Furosemide + rofecoxib 127 ± 5 422 ± 13 4.8 ± 0.4 37.1 ± 2.1 0.43 ± 0.07
Furosemide + cyclosporine A + rofecoxib 145 ± 7b 465 ± 14b 2.0 ± 0.2b 37.8 ± 2.2 0.43 ± 0.08
Data are mean ± SEM; N = 8.
aP < 0.05 compared with control; bP < 0.05 compared with furosemide-treated rats.
RESULTS
Influence of furosemide, CsA, and rofecoxib treatment
on blood pressure, heart rate, daily body weight gain,
hematocrit, and creatinine clearance
Systolic blood pressure of control rats was 122 ± 5 mm
Hg. Treatment with CsA, rofecoxib, or the combination of
CsA with rofecoxib increased systolic blood pressure to
141 ± 5, 139 ± 4, or 145 ± 6 mm Hg, respectively. Systolic
blood pressure of furosemide-treated animals was 117 ±
4 mm Hg. Additional treatment with CsA or rofecoxib
increased blood pressure to 129 ± 5 or 127 ± 5 mm Hg,
respectively. The combination of furosemide with CsA
and rofecoxib increased systolic blood pressure to 145 ±
7 mm Hg (Table 1). Heart rate of control rats was 388 ±
12 bpm. Rofecoxib treatment did not alter heart rate. CsA
or the combination of CsA with rofecoxib increased heart
rate to 432 ± 13 or 435 ± 11 bpm, respectively. Heart rate
of furosemide-treated animals was 428 ± 13 bpm and in-
creased during co-administration of CsA or CsA in com-
bination with rofecoxib to 462 ± 16 or 465 ± 14 bpm,
respectively (Table 1). Daily body weight gain was de-
creased to about 80% of control values during treatment
with CsA or during treatment with the combination of
CsA and rofecoxib. Rofecoxib had no influence on the
body weight gain. Furosemide treatment decreased daily
body weight gain to about 55% of control values. Ad-
ditional treatment with rofecoxib did not change body
weight gain. Additional treatment with CsA or the com-
bination of CsA with rofecoxib further decreased daily
body weight gain to about 40% of furosemide-treated
rats (Table 1). The hematocrit was not altered by any
treatment maneuver (Table 1). Creatinine clearance was
not altered by CsA, rofecoxib, furosemide, or the com-
bination of CsA with rofecoxib. Furthermore, creatinine
clearances of furosemide-treated rats were not altered by
any additional co-treatment (Table 1).
Plasma levels, tissue levels, and daily urinary excretion
of furosemide
Plasma level of furosemide was 4.93 ± 0.65 lg/mL for
furosemide-treated rats and did not change during addi-
tional treatment with CsA (4.78 ± 0.57 lg/mL), rofecoxib
(4.48 ± 0.48 lg/mL), or the combination of CsA with ro-
fecoxib (5.13 ± 0.54 lg/mL). The tissue concentration of
furosemide in the renal cortex of furosemide-treated rats
was 7.22 ± 1.46 lg/g wet weight for furosemide-treated
rats and did not change during additional treatment with
CsA (9.14 ± 1.55 lg/g wet weight), rofecoxib (7.07 ±
1.08 lg/g wet weight), or the combination of CsA with
rofecoxib (9.20 ± 1.21 lg/g wet weight). The daily uri-
nary excretion of furosemide was 5.79 ± 0.64 mg for
furosemide-treated rats and did not change during ad-
ditional treatment with CsA (4.96 ± 1.32 mg), rofecoxib
(5.87 ± 0.60 mg), or the combination of CsA with rofe-
coxib (6.57 ± 0.54 mg).
Influence of furosemide, CsA, and rofecoxib treatment
on COX-1 and COX-2 mRNA abundance in different
kidney zones
COX-1 mRNA was detected by RNase protection as-
say in renal cortex and outer and inner medulla, with
the highest expression in the inner medulla. In the renal
cortex, COX-1 mRNA was not altered by any treatment
maneuver (Fig. 1A). Furosemide treatment decreased
COX-1 mRNA abundance in the outer and inner medulla
to about 50% of control levels (Fig. 1B and C). CsA, ro-
fecoxib, or the combination of CsA with rofecoxib did
not influence COX-1 mRNA abundance at basal levels
nor during additional treatment with furosemide (Fig. 1B
and C).
COX-2 mRNA expression also displayed a gradient
from the cortex to the inner medulla, where the high-
est expression of COX-2 mRNA was found. Rofecoxib
had no effect on COX-2 mRNA expression in any kidney
zone (Fig. 2). CsA and the combination of CsA with rofe-
coxib clearly suppressed basal COX-2 mRNA abundance
in the renal cortex and outer and inner medulla to about
25%, 45%, and 25% of basal values, respectively (Fig. 2).
Furosemide treatment increased COX-2 mRNA abun-
dance in the renal cortex about twofold and suppressed
COX-2 mRNA abundance in the inner medulla to about
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Fig. 1. Effect of furosemide, cyclosporine A (CsA), rofecoxib, or their
combinations on cyclooxygenase 1 (COX-1) mRNA abundance in the
rat renal cortex (A) and outer (B) and inner medulla (C). Furosemide
decreased COX-1 mRNA in the outer and inner medulla (mean ± SEM;
N = 8). ∗P < 0.05 compared with vehicle-treated control.
50% of control values (Fig. 2). Additional treatment with
CsA or the combination of CsA with rofecoxib decreased
furosemide-altered COX-2 levels in the renal cortex and
outer and inner medulla to about 15%, 45%, and 45% of
the respective furosemide levels (Fig. 2).
Influence of furosemide, CsA, and rofecoxib treatment
on renocortical COX-2 and COX-1 protein expression
Basal renocortical COX-2 protein expression was
clearly decreased by CsA or the combination of CsA
with rofecoxib to about 40% of control values. Rofe-
coxib alone had no influence on COX-2 protein levels.
Furosemide increased renocortical COX-2 protein levels
about twofold. The increase was not attenuated by ro-
fecoxib, but was decreased to about 20% by additional
treatment with CsA and to about 25% by additional
treatment with the combination of CsA with rofecoxib
(Fig. 3A). Renocortical COX-1 (Fig. 3B) and b-actin pro-
tein were not altered by any treatment maneuver.
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Fig. 2. Effect of furosemide, cyclosporine A (CsA), rofecoxib, or their
combinations on cyclooxygenase 2 (COX-2) mRNA abundance in the
rat renal cortex (A) and outer (B) and inner medulla (C). CsA decreased
basal as well as furosemide-stimulated renocortical COX-2 mRNA
abundance (A) and decreased COX-2 mRNA in the outer medulla of
control or furosemide treated rats (B). CsA further decreased COX-2
mRNA abundance in the rat inner medulla of vehicle and furosemide
treated rats (C) (mean ± SEM; N = 8). ∗P < 0.05 compared with vehicle-
treated control. †P < 0.05 compared with furosemide-treated rats.
Influence of furosemide, CsA, and rofecoxib treatment
on renocortical prostanoid levels
The basal formation of renocortical PGE2 decreased
to about 65% of control values by treatment with CsA,
rofecoxib, or the combination of CsA with rofecoxib.
Furosemide treatment increased renocortical PGE2 con-
centration 1.4-fold and this increase was attenuated by
co-administration of CsA, rofecoxib, or the combination
of CsA with rofecoxib (Fig. 4A). The basal formation
of renocortical 6-keto PGF1a decreased to about 70%
of control values by treatment with CsA, rofecoxib, or
the combination of CsA with rofecoxib. Furosemide in-
creased renocortical 6-keto PGF1a concentration 1.4-fold
and this increase was attenuated by co-administration of
CsA, rofecoxib, or a combination of both (Fig. 4B). Reno-
cortical TxB2 formation was not altered by any treatment
maneuver (Fig. 4C).
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Fig. 3. Renocortical cyclooxygenase 2 (COX-2) (A) and COX-1 (B)
protein levels in rats treated with either vehicle or furosemide and in
addition with cyclosporine A (CsA), rofecoxib, or the combination of
rofecoxib with CsA. The insert shows representative blots for COX-1
and COX-2 protein (−, untreated; +, treated). The furosemide induced
increase in COX-2 protein expression was attenuated by CsA given
alone or in combination with rofecoxib, whereas rofecoxib had no in-
fluence (A). COX-1 protein abundance was not influenced by any treat-
ment maneuver (B) (mean ± SEM; N = 8). ∗P < 0.05 compared with
vehicle-treated control; †P < 0.05 compared with furosemide-treated
rats.
Influence of furosemide, CsA, and rofecoxib treatment
on renal prostanoid excretion
Daily urinary excretion of PGE2 decreased to about
60% of control values by CsA and by rofecoxib treat-
ment. The combination of rofecoxib with CsA did not
further decrease PGE2 excretion. Furosemide treatment
increased PGE2 excretion about 2.5-fold. Co-treatment
with CsA or rofecoxib attenuated the furosemide-
induced excretion of PGE2 to about 45% of furosemide
levels. The combination of CsA with rofecoxib did not
further decrease PGE2 excretion (Fig. 5A).
Daily urinary excretion of 6-keto PGF1a , a metabolite
of prostacyclin, decreased to about 70% of control values
by treatment with CsA or rofecoxib. The combination
of rofecoxib with CsA did not further decrease 6-keto
PGF1a excretion. Furosemide treatment increased 6-keto
PGF1a excretion about fourfold and additional treat-
ment with CsA or rofecoxib attenuated the furosemide-
induced excretion of 6-keto PGF1a . The combination
of CsA with rofecoxib did not further decrease 6-keto
PGF1a excretion (Fig. 5B).
Daily urinary excretion of TxB2, a metabolite of TxA2,
increased 2.5-fold over basal levels by CsA treatment,
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Fig. 4. Renocortical prostaglandin E2 (PGE2) (A), 6-keto prostag-
landin F1a (6-keto PGF1a) (B), and thromboxane B2 (TxB2) (C) levels
in rats treated with either cyclosporine A (CsA), rofecoxib, furosemide,
or the combination of CsA with rofecoxib. CsA, rofecoxib, and the com-
bination of CsA with rofecoxib decreased basal as well as furosemide
stimulated tissue levels of PGE2 (A) and 6-keto PGF1a (B). Tissue lev-
els of TxB2 were not altered by any treatment maneuver (C) (mean ±
SEM; N = 8). ∗P < 0.05 compared with vehicle-treated control; †P <
0.05 compared with furosemide-treated rats.
and decreased to about 70% of basal levels by rofecoxib
treatment. Rofecoxib also attenuated the CsA-induced
rise in TxB2 excretion. Furosemide treatment increased
TxB2 excretion about twofold and additional treatment
with CsA further increased TxB2 excretion. Rofecoxib
treatment attenuated these increases to about 50% of
the levels found in furosemide-treated rats (Fig. 5C).
Influence of furosemide, CsA, and rofecoxib treatment
on water, sodium, and potassium excretion
Daily urine excretion of control rats was 107 ± 12 mL/
day × kg body weight. CsA and the combination of
CsA with rofecoxib, but not rofecoxib alone, decreased
daily urine excretion to about 75% of control values.
Furosemide treatment increased daily urine excretion
about 7.5-fold. The increase was clearly attenuated by
co-administration of CsA, rofecoxib, or the combination
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Fig. 5. Urinary prostaglandin E2 (PGE2) (A), 6-keto prostaglandin
F1a (6-keto PGF1a) (B), and thromboxane B2 (TxB2) (C) excretion in
rats treated with either cyclosporine A (CsA), rofecoxib, furosemide, or
the combination of CsA with rofecoxib. CsA and rofecoxib decreased
basal as well as furosemide stimulated daily urinary excretion of PGE2
(A) and 6-keto PGF1a (B). CsA increased TxB2 excretion, what was
attenuated by additional rofecoxib treatment (C). Rofecoxib decreased
basal as well as furosemide-induced TxB2 excretion (mean ± SEM; N =
8). ∗P <0.05 compared with vehicle-treated control; †P <0.05 compared
with furosemide-treated rats; ‡P < 0.05 compared with CsA.
of CsA with rofecoxib to about 40% of furosemide levels
(Fig. 6A).
Daily sodium excretion of control rats was 38 ± 4 mval/
day × kg body weight and was not altered by rofecoxib
treatment. CsA alone or in combination with rofecoxib
decreased basal sodium excretion to about 70% of con-
trol values. Furosemide treatment increased daily sodium
excretion about 4.5-fold. This increase was clearly atten-
uated by CsA, rofecoxib, or the combination of both to
about 35% of furosemide levels (Fig. 6B).
Daily potassium excretion of control rats was 26 ±
3 mval/day × kg body weight and was not altered by ro-
fecoxib or furosemide. CsA, whether given alone or in
combination with rofecoxib, decreased potassium excre-
tion (Fig. 6C) to about 65% of the respectative control
values.
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Fig. 6. Urinary volume (A) and daily urinary sodium (B) and potas-
sium excretion (C) in rats treated with either vehicle and furosemide and
in addition with cyclosporine A (CsA), rofecoxib, or the combination
of rofecoxib with CsA. Furosemide increased urinary volume (A) and
daily urinary sodium excretion (B). These increases were attenuated by
co-administration of rofecoxib, CsA, or a combination of rofecoxib with
CsA. Urinary potassium excretion was decreased by CsA treatment (C)
(mean ± SEM; N = 8). ∗P < 0.05 compared with vehicle-treated control;
†P < 0.05 compared with furosemide-treated rats.
Influence of furosemide, CsA, and rofecoxib treatment
on PRA and renal renin mRNA abundance
PRA was 7.5 ± 0.9 ng angiotensin I (Ang I)/hour ×
mL in control rats. Treatment with CsA increased
PRA 1.8-fold and this increase was attenuated by ad-
ditional rofecoxib treatment. Rofecoxib alone did not
alter PRA. Furosemide increased PRA 6.6-fold and
co-administration of CsA further increased PRA. The
furosemide-induced rise in PRA as well as the increase
by additional CsA treatment was attenuated by co-
administration of rofecoxib to 30 ± 5 ng Ang I/hour ×
mL (Fig. 7A).
Similar results were obtained with regard to reno-
cortical renin mRNA abundance. CsA increased renin
mRNA abundance about twofold over control values
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Fig. 7. Plasma renin activity (PRA) (A) and renocortical renin mRNA
abundance (B) in rats treated with either vehicle or furosemide and in
addition with cyclosporine A (CsA), rofecoxib, or the combination of
rofecoxib with CsA. The furosemide induced raise in PRA was attenu-
ated by rofecoxib or the combination of rofecoxib with CsA. CsA fur-
ther increased PRA (A). The furosemide-induced increase in renocorti-
cal renin mRNA abundance was attenuated by rofecoxib or the combi-
nation of rofecoxib with CsA. CsA further increased renocortical renin
mRNA abundance (B) (mean ± SEM; N = 8). ∗P < 0.05 compared with
vehicle-treated control; †P < 0.05 compared with furosemide-treated
rats; ‡P < 0.05 compared with CsA.
and additional rofecoxib treatment attenuated this
increase. Rofecoxib alone had no effect on basal reno-
cortical renin mRNA abundance. Furosemide treatment
increased renin mRNA about 2.2-fold compared to basal
levels. Additional treatment with CsA further increased
renin mRNA abundance, which was attenuated by
additional rofecoxib treatment. Furthermore, the
furosemide-induced increase in renin mRNA abundance
was attenuated by rofecoxib (Fig. 7B).
Influence of furosemide, CsA, and rofecoxib treatment
on 6-keto PGF1a plasma levels
CsA increased 6-keto PGF1a plasma levels about
twofold (Fig. 8). Rofecoxib had no influence on basal
levels, but clearly prevented the CsA-induced rise in
6-keto PGF1a plasma levels (Fig. 8). Furosemide in-
creased 6-keto PGF1a plasma levels about 2.2-fold. Co-
administration of CsA further increased 6-keto PGF1a
plasma levels. Additionally, treatment with rofecoxib
decreased furosemide and CsA-induced 6-keto PGF1a
plasma levels (Fig. 8).
DISCUSSION
On the basis of observations that the renal actions of
loop diuretics are sensitive toward inhibition of COX-2 [5,
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Fig. 8. Plasma concentrations of 6-keto prostaglandin F1a (6-keto
PGF1a) in rats treated with either cyclosporine A (CsA), rofecoxib,
furosemide, or the combination of CsA with rofecoxib. Furosemide
increased plasma levels of 6-keto PGF1a . CsA further increased 6-
keto PGF1a levels. Rofecoxib attenuated the furosemide-stimulated
rise in plasma 6-keto PGF1a levels and attenuated the CsA-stimulated
increase in plasma levels of 6-keto PGF1a (mean ± SEM; N = 8). ∗P <
0.05 compared with vehicle-treated control; †P < 0.05 compared with
furosemide-treated rats; ‡P < 0.05 compared with CsA.
6] and because inhibitors of calcineurin phosphatase, like
CsA, decrease renal COX-2 expression [16], our study
aimed to characterize the interference of CsA with the
renal actions of loop diuretics, especially with regard to
diuresis and natriuresis.
The data obtained in this study clearly demonstrate that
the calcineurin inhibitor attenuates the well-established
increase in diuresis and natriuresis induced by the loop di-
uretic furosemide. Rats that have been treated with CsA
or furosemide had less weight gain, confirming previous
observations [20, 4]. The reduced weight gain of CsA-
treated rats may be related to a moderate drug-induced
diarrhea, because there was no observation of anorexia
as estimated by the food intake, which was in the range
of control rats. The furosemide-induced decrease in body
weight may be related to a decreased food intake dur-
ing the first 2 days after implantation of the osmotic
minipumps. However, the food intake returned to con-
trol levels from day 3 on. It should be noted that we did
not obtain evidence that the rats were volume depleted
after prolonged treatment with furosemide.
In accordance to previous observations, CsA treatment
increased systolic blood pressure [21]. Our data suggest
that the increment in arterial pressure induced by CsA
may be in part secondary to the increment in TxA2, as
reflected by increased daily urinary excretion of TxB2,
the stable metabolite of TxA2, but also secondary to an
increase in Ang II since we found that CsA increased
the activity of the renin system. We further observed an
increased heart rate in CsA-treated rats, suggesting an
activation of the sympathetic nervous system, as reported
by others [22, 23].
In line with previous reports, we found that CsA
inhibits renal COX-2 expression [16], that furosemide
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increases renocortical COX-2 expression [4, 6], that
furosemide down-regulates COX-2 and COX-1 expres-
sion in the rat medulla [24], and that rofecoxib has no ef-
fect on renal COX-1 and COX-2 expression up to 7 days
of treatment [13]. The opposite regulation of the COX
isoforms by furosemide in the renal cortex and inner
medulla has been previously described. Thus, it has been
suggested that inhibition of the salt transport in the loop
of Henle causes a selective stimulation of COX-2 expres-
sion in the macula densa [4], whereas down-regulation
of COX-2 and COX-1 expression in the inner medulla
of the rat kidney is likely related to a breakdown of the
papillary osmotic gradient [24]. Although CsA attenu-
ates COX-2 expression in the rat renal cortex and the
medulla, the precise mechanism involved in the opposite
regulation could not be answered from our findings and
needs further investigation.
We now found that CsA also attenuates furosemide-
stimulated COX-2 expression in the rat kidney cortex.
Further, CsA decreased renocortical PGE2 and 6-keto
PGF1a formation as well as daily urinary excretion of
PGE2 and 6-keto PGF1a in furosemide-treated rats like
the COX-2 blocker rofecoxib did. Although it is sug-
gested that the dose of rofecoxib used in our study is
selective for COX-2 in the rat [25, 26], rofecoxib may also
inhibit the COX-1 isoform, since there was a decrease in
the urinary excretion of TxB2. In addition, we found that
a combination of CsA with the COX-2 blocker rofecoxib
has no additive effect on the formation and excretion of
PGE2 and 6-keto PGF1a .
We further found that CsA treatment reduces natriure-
sis and diuresis confirming previous reports [20, 21]. The
antinatriuretic effect of CsA has long since been known,
but the precise mechanisms causing the decrease in na-
triuresis have not been really understood. It has been
suggested in this context that the decrease in sodium
excretion may be secondary to a CsA induced fall in
glomerular filtration rate (GFR) [20]. To investigate such
a possible influence of CsA or rofecoxib on GFR, we mea-
sured creatinine clearance. Confirming previous studies,
we found that neither CsA [27] nor COX-2 inhibition [28]
negatively influenced GFR, suggesting that a fall in GFR
is of minor relevance for the decrease in natriuresis in our
study.
It is well known, that prostanoids, especially PGE2,
increase natriuresis and diuresis [29–32]. At the cellular
level, PGE2 directly inhibits the reabsorption of NaCl in
the medullary thick ascending limb and in the collect-
ing duct [29–31]. This action of PGE2 may explain why
cyclooxygenase inhibitors cause sodium and water reten-
tion, an effect that predominantly occurs in the thick as-
cending limb of Henle [33]. In the thick ascending limb
of Henle the expression of the Na-K-2 Cl co-transporter
can be modulated by renal prostanoids in the way that
PGE2 decreases its expression and leads therefore to
an enhanced diuresis and sodium excretion [34]. In ad-
dition, the vasopressin-induced resorption of water in
the collecting duct is reduced by PGE2 [29]. With re-
gard to the data obtained in our study, it seems likely
that inhibition of renal PGE2 formation and urinary ex-
cretion by CsA attenuates the furosemide-induced na-
triuresis and diuresis. This conclusion would be further
supported by the finding that the COX-2 blocker rofe-
coxib has similar effects on renal PGE2 formation and
on natriuresis and diuresis in furosemide-treated rats.
Furthermore, a combination of CsA with rofecoxib had
no additive effects on PGE2 formation, natriuresis, and
diuresis.
Taken into consideration that the renin system and the
sympathetic nervous system is activated by CsA, the anti-
natriuretic and antidiuretic effect of CsA may also be in
part secondary to the activation of the renin system and
the sympathetic nervous system and therefore an addi-
tive effect may not be observed. Further, an additive ef-
fect may not be observed because of the differences in
blood pressure in the treatment groups. However, addi-
tional treatment with the angiotensin-converting enzyme
(ACE) inhibitor enalapril or the angiotensin II type 1
(AT1) receptor antagonist valsartan did not ameliorate
CsA-induced antinatriuresis in spontaneously hyperten-
sive rats, but attenuated CsA-induced hypertension [35].
Although, we cannot exclude further tubular effects of
CsA, which may influence natriuresis and diuresis in our
study, the results obtained demonstrate that there is an
association between furosemide induced natriuresis with
COX-2–derived prostanoids.
Aside from the effects on salt and water reabsorption,
PGE2 and in particular prostacyclin (PGI2) also stimu-
late renin synthesis and secretion [36, 37]. It has been
found that inhibition of COX activity reduces renin syn-
thesis and secretion [38]. Since macula densa cells can
express COX-2, it has been hypothesized that COX-2–
derived prostanoids might be the mediators of the mac-
ula densa control of renin secretion and renin synthesis
[10, 11]. Loop diuretics block salt transport, increase the
expression of COX-2 in the macula densa region, and
at the same time stimulate the activity of the renin sys-
tem in a COX-2–dependent fashion [4–6]. Therefore, it
is an obvious conclusion that the stimulatory effect of
loop diuretics is mediated by the macula densa. How-
ever, our data show that CsA markedly attenuates the
stimulation of COX-2 expression and of renal prostanoid
excretion by furosemide but does not prevent the stimu-
lation of the renin system by furosemide, while a COX-2
blocker inhibits the stimulation of the renin system by
furosemide in presence of CsA. It appears, therefore,
as if COX-2–derived prostanoids but not macula densa–
derived prostanoids or even renal prostanoids in general
are required for the effect of loop diuretics on the renin
system.
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We are aware that a marked decrease of COX ex-
pression in the medulla, which is the main site of renal
prostanoid synthesis, is at first glance difficult to recon-
cile with the enhancement of renal prostanoid excretion
by furosemide, but there is evidence that loop diuret-
ics increase PGI2 formation in extrarenal tissues leading
to increased plasma PGI2 formation, for example [39–
41]. Thus, it has been shown that furosemide stimulates
prostacyclin levels in human endothelial cells, suggesting
that the vasculature could be a predominant site of PGI2
synthesis [41]. Therefore, we determined plasma concen-
tration of PGI2 as indicated by 6-keto PGF1a levels. Con-
trol levels of 6-keto PGF1a , which were in the range of a
previous report of us [42], were increased by treatment
with CsA, furosemide, and much stronger by the com-
bination of CsA with furosemide. We further found that
additional treatment with the selective COX-2 blocker
rofecoxib attenuated these increases, suggesting that
COX-2 is responsible for increased PGI2 plasma levels
and, since PGI2 is known to be a potent stimulator of the
renin system [36, 37], increases in plasma PGI2 levels may
be involved in the stimulation of the renin system during
CsA and furosemide treatment. We speculate, therefore,
that furosemide-induced stimulation of the renin systems
may partially depend on extrarenal prostanoid forma-
tion. However, the question arises, where the increased
formation of PGI2 during CsA treatment comes from.
This question could not be answered from our study, but
it has been shown in vitro that rat aortic endothelial cells
increase the synthesis of prostacyclin in response to CsA
[43], suggesting that CsA increases the formation of PGI2
in endothelial cells. However, it is generally believed that
PGI2 is an autacoid that is quickly metabolized to 6-keto
PGF1a before reaching to the kidney and given the case
that a small portion of not metabolized PGI2 reaches the
kidney, as it has been shown for intravenous administra-
tion of PGI2 [44, 45], the increment of PGI2 may increase
not only renin [44, 45] release but also urinary sodium and
water excretion [44], a possibility that would favor our
findings for furosemide treatment, but not for CsA, sug-
gesting that there are additional tubular effects involved
in CsA-associated antinatriuresis and antidiuresis. Fur-
ther, the small increment of prostacyclin in our study
may be sufficient to activate the prostacyclin receptor
[46].
Although differences between the treatment groups in
the levels of blood pressure, renin, and probably sym-
pathetic activity may complicate a comparison, our data
suggest that CsA attenuates furosemide-induced natri-
uresis, likely by the inhibition of COX-2–mediated re-
nal prostanoid formation. Since the furosemide-induced
stimulation of the renin system is not attenuated by CsA
but by COX-2 inhibitors, we speculate that extrarenal
COX-2–derived prostanoids may be involved in the stim-
ulation of the renin system by loop diuretics.
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